Navigation Links
Arpida Announces Agenda Items for Shareholders Meeting
Date:4/15/2008

authorised capital) or via conversion of bonds (conditional capital). Arpida currently has no intention to use this capital. This proposed additional capital cannot be used for the granting of employee options.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resi
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
2. Arpida Announces Full Year 2007 Financial Results
3. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
4. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
5. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
6. Arpida-Supported CME Symposium Available Online
7. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
8. Arpida Presents Preclinical Data on AR-2474 at ICAAC
9. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
10. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
11. Arpida Interim Results for six Months to 30 June 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") ... approach for protecting personal data in Clinical Study ... and others. The document describes an approach to ... CSRs and other related clinical trial documents, and ... goal of the TransCelerate CSR Redaction approach is ...
(Date:9/2/2014)... September 02, 2014 Opertech Bio, ... highly efficient, cost effective approach to sensory evaluation, ... 8,820,265 by the U.S. Patent and Trademark Office, ... , “Opertech’s taste evaluation technology called ... automated high throughput system for rapid characterization of ...
(Date:9/2/2014)... /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced today ... Officer, will present at the Rodman & Renshaw 16 th ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. ... the presentation will be accessible by visiting the Oncothyreon website ... About Oncothyreon Oncothyreon is a ...
(Date:9/2/2014)... NC (PRWEB) September 02, 2014 ... of its 11th clinical research site: PMG Research of ... ownership and operation of the clinical research department at ... expanding PMG’s presence in eastern North Carolina. This new ... For the patients in Rocky Mount and the surrounding ...
Breaking Biology Technology:TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3
... was heading to the tiny island nation of The Maldives ... By all reports and expectations, she would be off the grid. ... , ,Or maybe not. After 36 hours in transit, we ... way through customs and out into the humid night air. Greeting ...
... following article is Part I of a three-part series ... series will address what business organizations and educational institutions ... , , Milwaukee, Wis. - John Psuik ... impact the growth of his company, Developer One ...
... Cancer Institute has awarded a five-year, $1.4 million renewal ... study the growth of blood vessels in brain tumors. , ... was first awarded in 2003. Kathleen Schmainda, associate professor of ... investigators are developing what they call magnetic resonance imaging contrast ...
Cached Biology Technology:Coveted vacation "disconnect" was elusive 2Coveted vacation "disconnect" was elusive 3IT workforce development: Losing the numbers game 2IT workforce development: Losing the numbers game 3IT workforce development: Losing the numbers game 4IT workforce development: Losing the numbers game 5
(Date:9/2/2014)... the University of Warwick in the UK and the ... Journal Early Human Development , has found that ... birth and the use of mechanical ventilation are key ... Mathematic abilities are crucial for lifelong academic attainment. Impairments ... Earlier studies of children who are born very preterm ...
(Date:9/2/2014)... battle between our immune systems and cholera bacteria, humans ... as phages. In a new study, researchers from Tufts ... Public Health Laboratory, and elsewhere, report that phages can ... order to survive. Importantly, the study published in ... from phage predation occurs during human infection. , First ...
(Date:9/2/2014)... Best-selling author Sam Kean stops by Reactions this ... 50-foot super shark that, despite what "Shark Week" may ... about it at http://youtu.be/KhFygIoW_MA . , Kean,s book, ... Love and the History of the World from the ... treatment in a 10-episode video series produced for the ...
Breaking Biology News(10 mins):Mechanical ventilation a key indicator for pre-term children's math problems 2War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3
... CLEVELAND/ORLANDO University Hospitals Case Medical Center researchers could ... second chancejust not as they originally thought. LateTIME ... from bone marrow that were believed to have the ... injected into the heart within two weeks of the ...
... suffering from heart failure due to a previous myocardial ... year following an investigative treatment that involved infusing them ... 4 percent improvement average the researchers projected for the ... published today (Nov. 14) in The Lancet ...
... to understanding what drives tumor metastasis, as laboratory models ... their own growth. In a recent issue of ... Association for Cancer Research, Ral A. Ruggiero, Ph.D., a ... the National Academy of Medicine in Buenos Aires, Argentina, ...
Cached Biology News:Post heart attack recovery may not be aided by stem cell injections, but trial demonstrates promise 2Results triple researchers' projections with use of adult stem cells for heart failure 2